These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38715793)

  • 21. Global research on artificial intelligence in thyroid-associated ophthalmopathy: A bibliometric analysis.
    Zhang X
    Adv Ophthalmol Pract Res; 2024; 4(1):1-7. PubMed ID: 38196774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Choice the appropriate therapy according to the clinical features of the thyroid associated ophthalmopathy].
    Xiao LH
    Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1060-2. PubMed ID: 17415960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.
    Wang Y; Smith TJ
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathologic study of extraocular muscles in thyroid-associated ophthalmopathy coexisting with ocular myasthenia gravis: a case report.
    Ma R; Cheng Y; Gan L; Zhou X; Qian J
    BMC Ophthalmol; 2020 Apr; 20(1):166. PubMed ID: 32321476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2021 update on thyroid-associated ophthalmopathy.
    Neag EJ; Smith TJ
    J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
    Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
    Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid eye disease: a review.
    Weiler DL
    Clin Exp Optom; 2017 Jan; 100(1):20-25. PubMed ID: 27701774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy.
    Jang SY; Lee KH; Oh JR; Kim BY; Yoon JS
    Yonsei Med J; 2015 Sep; 56(5):1389-94. PubMed ID: 26256985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Practical Guidelines Management of Graves Ophthalmopathy.
    Subekti I; Soewondo P; Soebardi S; Darmowidjojo B; Harbuwono DS; Purnamasari D; Tarigan TJE; Wisnu W; Tahapary DL; Kurniawan F; Sidik M; Nusanti S; Dewiputri S; Suharko H; Suardana GG; Suroyo I; Wulani V; Siswoyo AD; Gondhowiardjo S; Kodrat H
    Acta Med Indones; 2019 Oct; 51(4):364-371. PubMed ID: 32041923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid ophthalmopathy.
    Levy J; Sobel R; Marcus M; Lifshitz T
    Minerva Endocrinol; 2005 Dec; 30(4):247-65. PubMed ID: 16319812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface.
    Novaes P; Diniz Grisolia AB; Smith TJ
    Clin Diabetes Endocrinol; 2016; 2():19. PubMed ID: 28702253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and Clinical Features of Thyroid-associated Orbitopathy in Accra.
    Ackuaku-Dogbe EM; Akpalu J; Abaidoo B
    Middle East Afr J Ophthalmol; 2017; 24(4):183-189. PubMed ID: 29422752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reevaluation of the prevalences of serum autoantibodies reactive with "64-kd eye muscle proteins" in patients with thyroid-associated ophthalmopathy.
    Kubota S; Gunji K; Stolarski C; Kennerdell JS; Wall J
    Thyroid; 1998 Feb; 8(2):175-9. PubMed ID: 9510127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of Corneal Langerhans Cells by In Vivo Confocal Microscopy in Thyroid-Associated Ophthalmopathy.
    Wu LQ; Cheng JW; Cai JP; Le QH; Ma XY; Gao LD; Wei RL
    Curr Eye Res; 2016 Jul; 41(7):927-32. PubMed ID: 26735162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.
    Rajaii F; McCoy AN; Smith TJ
    Expert Rev Ophthalmol; 2014 Jun; 9(3):227-234. PubMed ID: 25544859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves' Disease.
    Zhao J; Lin B; Deng H; Zhi X; Li Y; Liu Y; Bible PW; Li Q; Xu B; Wei L; Yang H; Huang D
    Curr Mol Med; 2018; 18(2):83-90. PubMed ID: 29974826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
    Gopinath B; Musselman R; Beard N; El-Kaissi S; Tani J; Adams CL; Wall JR
    Clin Exp Immunol; 2006 Jul; 145(1):56-62. PubMed ID: 16792674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Graves' ophthalmopathy.
    González-García A; Sales-Sanz M
    Med Clin (Barc); 2021 Feb; 156(4):180-186. PubMed ID: 33069387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.